SelectScience
Join Free
NewsClinical Diagnostics

Akoya Biosciences launches PhenoCode Signature Panels to accelerate development of predictive biomarkers for cancer immunotherapy

Akoya Biosciences

Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers

9 Nov 2022
Blake Forman
Content Creator

Product news

Akoya Biosciences, Inc., has announced the launch of PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery and validation on the PhenoImager® platforms. Each of the customizable multiplex panels includes key markers for phenotyping the tumor microenvironment (TME) and immune status. When combined with the high-speed and robust imaging of the PhenoImager platforms, a rapid, quantitative, end-to-end spatial phenotyping workflow is enabled. The workflow accelerates the development and validation of predictive signatures and prognostic biomarkers for immuno-oncology applications.

Poster presentations and a symposium describing the application of PhenoCode Signature Panels will be offered at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.

Akoya’s symposium, titled ‘Supercharging Spatial Signature Development’, will be held on November 10 from 7:30 pm to 9:00 pm ET in BCEC 156 at the Boston Convention Center. Speakers include:

  • Patrick Savickas Ph.D., Immunochemist, HistoWiz
  • Arutha Kulasinghe, Ph.D., Senior Research Fellow, University of Queensland
  • Oliver Braubach, Ph.D., Head of Applications, Akoya Biosciences

“The rapidly expanding immuno-oncology therapeutic and clinical trial landscape is necessitating the need for more predictive tissue-based biomarker solutions,” said Brian McKelligon, Chief Executive Officer of Akoya Biosciences. “The PhenoCode Signature Panels provide our translational and clinical partners with a ready-made and customizable solution to rapidly advance their biomarker programs.”

The PhenoCode Signature chemistry represents an important milestone in Akoya’s commitment to creating a suite of platform solutions from discovery to diagnostics. As a powerful hybrid of Akoya’s legacy CODEX and Opal assays, the PhenoCode Signature Panels create a continuum of methodologies, enabling translational and clinical researchers to perform discovery on the PhenoCycler®-Fusion and validation on the PhenoImager platforms.

“Invicro is excited to partner with Akoya for early access to the new PhenoCode Signature Panels, which will simplify approaches to create rich, contextual biomarker data and help us accelerate the discovery and validation of immunotherapy biomarkers,” said Joseph Krueger, Ph.D., Vice President of Invicro’s Advanced Pathology Services. “What is particularly unique is that the panels deliver the efficiency of an off-the-shelf assay with the power of customization to enable rapid deployment of panels to follow the natural process of scientific exploration.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Related products

Request Quote for All Products

PhenoImager® Fusion

Akoya Biosciences

The PhenoImager ® ; Fusion system is a whole-slide, single-cell resolution, ultrafast multispectral imager ideal for standard throughput brightfield and fluorescence imaging applications. This imaging platform can be integrated with the PhenoCycler ® ; system (formerly CODEX ® ) for ultra high-plex spatial discovery at scale.

(2)

PhenoImager® HT

Akoya Biosciences

PhenoImager ® HT (formerly Vectra ® Polaris™) is the fastest and most highly cited whole-slide, single-cell resolution imaging platform for spatial phenotyping and the development of spatial signatures. Featuring Akoya’s patented Multispectral Imaging (MSI) and spectral unmixing technologies, this platform can be easily integrated into high-throughput workflows to accommodate projects regardless of your scale. 

(2)

Links

Akoya BiosciencesCompany website

Tags

High-Throughput ScreeningHigh-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :MultiplexHigh ThroughputHigh throughput experiments allow the simultaneous processing of several samples. This parallelization reduces the cost per experiment and increases reproducibility and output volume of data.ImmunotherapyImmunotherapy is a treatment approach that utilizes the body�s immune system to fight diseases, especially cancer. It includes therapies such as monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapy. Immunotherapy is a rapidly growing area of research in oncology and autoimmune diseases. Browse our peer-reviewed product directory to find the best immunotherapy tools, compare products, check reviews, and get pricing directly from manufacturers.TumorsTumor research focuses on understanding abnormal cell growth that leads to cancer. Identifying biomarkers, studying tumor microenvironments, and developing targeted therapies are critical for advancing cancer treatment. Early detection and personalized treatment options are key to improving outcomes for patients. Browse our peer-reviewed product directory to explore tools for tumor research, diagnostics, and cancer therapies; compare products, read customer reviews, and get pricing directly from manufacturers.Phenotypic ScreeningPhenotypic screening assesses cellular responses to compounds, enabling drug discovery and target identification. This technique is pivotal in finding effective treatments for complex diseases. Discover phenotypic screening platforms and tools with peer-reviewed comparisons and pricing in our directory.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.

Related articles

Akoya Biosciences launches PhenoCode Signature Panels to accelerate development of predictive biomarkers for cancer immunotherapy